(3,5-Difluorophenyl)thiourea, 97%, 1g

1,2,3,4-TETRAHYDRO-QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER HCL, 97.0%, 5g

1,2-BENZENEDIAMINE, 4-(4-AMINOPHENOXY)-, 95%, 200mg

1-Chloroadamantane, min. 98%, for synthesis, 5 g, glass packaging

Ethyl 3-bromo-6-iodoimidazo[1,2-a]pyridine-2-carboxylate, 90%, 250mg

2,4-Dichloroquinoline>98.0%(GC)25g

[5-(3-Trifluoromethoxy-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-carbamic acid tert-butyl ester, 95.0%, 1g

(2R,3R,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)tetrahydrofuran-3-ol, 95.0%, 500mg

Methyl 2-oxopentanoate, 95.0%, 250mg

6-Bromo-2H-benzo[e][1,3]oxazine-2,4(3H)-dione, 98+%, 250mg

2-(3-((2-Ethylphenoxy)methyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97%, 250mg

3,5-Dimethoxyphenol, 98.0%, 5g

8-Oxa-2-azaspiro[4.5]decane hydrochloride, 97%, 1g